Literature DB >> 25845436

Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Natashia Swalve1, Steven T Pittenger, Rick A Bevins, Ming Li.   

Abstract

RATIONALE: Tobacco use is a serious health problem in the USA, and this problem is potentiated in patients with schizophrenia. The reward system is implicated in schizophrenia and may contribute to the high comorbidity between nicotine use and schizophrenia, but very little research has been done on the topic. The reward-enhancement effect of nicotine has been shown to be important in nicotine use, but there have been no studies on this effect in animal models of schizophrenia.
OBJECTIVES: This study was designed to determine the effects of phencyclidine, used to model negative symptoms of schizophrenia, on self-administration of nicotine with or without a co-occurring sensory reinforcer [i.e., visual stimulus (VS)] in rats.
METHODS: Phencyclidine (2.0 mg/kg) was administered before each of seven nicotine self-administration sessions (0.01 mg/kg/inf) after which rats (n = 8-9 per group) were given 7 days of extinction without phencyclidine pretreatment. Reinstatement using phencyclidine (2.0 mg/kg), nicotine (0.2 mg/kg), and yohimbine (1.25 mg/kg, a pharmacological stressor) was tested after extinction to determine if previous exposure to phencyclidine would alter reinstatement of active lever pressing.
RESULTS: Phencyclidine initially decreased nicotine self-administration but only in the groups with a concurrent VS. This decrease in self-administration dissipated after 5 days. During reinstatement, rats that had previously received phencyclidine during self-administration with a VS were more sensitive to stress-induced reinstatement than any other group.
CONCLUSIONS: These results show a transitory effect of phencyclidine on nicotine self-administration. Phencyclidine may induce a potential sensitivity to pharmacological stressors contributing to reinstatement of nicotine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25845436      PMCID: PMC4515150          DOI: 10.1007/s00213-015-3923-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  76 in total

Review 1.  Addiction and the brain antireward system.

Authors:  George F Koob; Michel Le Moal
Journal:  Annu Rev Psychol       Date:  2008       Impact factor: 24.137

2.  The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.

Authors:  Z Abdul-Monim; G P Reynolds; J C Neill
Journal:  J Psychopharmacol       Date:  2003-03       Impact factor: 4.153

3.  Psychological model for smoking behavior.

Authors:  S S Tomkins
Journal:  Am J Public Health Nations Health       Date:  1966-12

4.  Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs.

Authors:  Susan M Cochran; Matthew Kennedy; Clare E McKerchar; Lucinda J Steward; Judith A Pratt; Brian J Morris
Journal:  Neuropsychopharmacology       Date:  2003-02       Impact factor: 7.853

5.  Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm.

Authors:  M Davis; D E Redmond; J M Baraban
Journal:  Psychopharmacology (Berl)       Date:  1979-10       Impact factor: 4.530

6.  Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia.

Authors:  Sara L Dolan; Kristi A Sacco; Angelo Termine; Aisha A Seyal; Melissa M Dudas; Jennifer C Vessicchio; Bruce E Wexler; Tony P George
Journal:  Schizophr Res       Date:  2004-10-01       Impact factor: 4.939

7.  Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement.

Authors:  Eric C Donny; Nadia Chaudhri; Anthony R Caggiula; F Fay Evans-Martin; Sheri Booth; Maysa A Gharib; Laure A Clements; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

8.  Pharmacological blockade of alpha2-adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys.

Authors:  Buyean Lee; Stefan Tiefenbacher; Donna M Platt; Roger D Spealman
Journal:  Neuropsychopharmacology       Date:  2004-04       Impact factor: 7.853

9.  The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse.

Authors:  Jack D Shepard; Jennifer M Bossert; Shirley Y Liu; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2004-06-01       Impact factor: 13.382

10.  Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice.

Authors:  W J Freed; D R Weinberger; L A Bing; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  4 in total

1.  Nicotine Self-administration Is Not Increased in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia.

Authors:  Jillian J Weeks; Laura E Rupprecht; Anthony A Grace; Eric C Donny; Alan F Sved
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

2.  Investigating sex differences and the effect of drug exposure order in the sensory reward-enhancing effects of nicotine and d-amphetamine alone and in combination.

Authors:  Kathleen R McNealy; Sydney D Houser; Scott T Barrett; Rick A Bevins
Journal:  Neuropharmacology       Date:  2021-10-19       Impact factor: 5.250

3.  A behavioral economic perspective on smoking persistence in serious mental illness.

Authors:  Jennifer W Tidey
Journal:  Prev Med       Date:  2016-05-16       Impact factor: 4.018

4.  Sex differences in attenuation of nicotine reinstatement after individual and combined treatments of progesterone and varenicline.

Authors:  Natashia Swalve; John R Smethells; Marilyn E Carroll
Journal:  Behav Brain Res       Date:  2016-04-21       Impact factor: 3.332

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.